Login to Your Account

BMS Opts to Keep MATCH Burning with Tranzyme Pharma

By Mari Serebrov
Washington Editor

Wednesday, November 9, 2011
The match Tranzyme Pharma Inc. struck with Bristol-Myers Squibb Co. (BMS) two years ago will continue to spark the discovery of potential new macrocyclic drug candidates – at least for an additional six months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription